NL - Forbion and Inventages invest EUR 2.5m in AM-Pharma

Irmak
06 August 2007

Tweet
Facebook
LinkedIn
Google plus
Send to

Forbion Capital Partners and Inventages Venture Capital have invested EUR 2.5m in their portfolio company AM-Pharma, a Dutch biopharmaceuticals business. The investment will be followed by a Series-C financing round, for which the company is in discussion with European and American investors. The existing investors will contribute to the upcoming round as well, which will close before the end of this year.

AM-Pharma develops endogenous proteins to combat disease. The cash raised in the upcoming round will allow the company to generate Phase II efficacy and safety data for two products; recombinant human Alkaline Phosphatase and Anti-Microbial Peptide hLF1-11, in four therapeutic indications; Acute Renal Failure; Ulcerative Colitis; hospital acquired bacterial infections and systemic Candida infection, in the next three years. AM-Pharma recently announced positive results in two Phase IIa studies with Alkaline Phosphatase in Acute Renal Failure and Ulcerative Colitis, while Anti-Microbial Peptide hLF1-11 showed to be safe in a first trial in bone marrow transplant patients.